Skip to main content

Table 2 FA score, sociodemographic characteristics, and risk factors

From: Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors

Characteristic (n = 67)

Mean (SD)

Mean rank

p-value

Nationality

 Lebanese (n = 60)

41.11 (32.24)

33.40

0.452

 Non-Lebanese (n = 7)

50.79 (31.98)

39.14

Marital status

 Non married (n = 9)

35.80 (32.29)

30.22

0.524

 Married (n = 58)

43.10 (32.24)

34.59

Education level

 Primary (n = 9)

28.40 (24.29)

24.89

0.097

 Secondary (n = 41)

48.51 (31.70)

36.76

 University (n = 15)

34.07 (34.24)

27.60

Socioeconomic level

 Low (n = 3)

18.52 (16.97)

18.83

0.177

 Middle (n = 58)

44.44 (32.58)

35.07

 High (n = 5)

24.44 (26.53)

24.10

Professional activity

 Yes (n = 22)

48.48 (34.55)

37.55

0.289

 No (n = 45)

39.01 (30.76)

32.27

Alcohol

 No (n = 59)

43.13 (31.36)

34.64

0.460

 Yes (n = 8)

34.72 (38.69)

29.31

Tobacco

 No (n = 45)

45.43 (31.14)

36.01

0.353

 Yes (n = 19)

37.42 (33.58)

31.11

 Previous smoker (n = 3)

22.22 (38.49)

22.17

Allergy

 No (n = 62)

39.96 (31.46)

32.77

0.065

 Yes (n = 5)

68.89 (30.83)

49.20

Dyslipidemia

 No (n = 56)

40.08 (31.90)

32.85

0.266

 Yes (n = 11)

52.53 (32.62)

39.86

Diabetes

 No (n = 62)

42.11 (33.19)

33.89

0.865

 Yes (n = 5)

42.22 (14.49)

35.40

Hypertension

 No (n = 50)

44.00 (32.53)

35.20

0.379

 Yes (n = 17)

36.60 (31.12)

30.47

Oral antidiabetics

 No (n = 62)

42.11 (33.19)

33.89

0.865

 Yes (n = 5)

42.22 (14.49)

35.40

Antihypertensive drugs

 No (n = 52)

42.52 (32.76)

34.31

0.806

 Yes (n = 15)

40.74 (30.77)

32.93

Dyslipidemia treatment

 No (n = 57)

39.38 (32.06)

32.40

0.103

 Yes (n = 10)

57.78 (39.07)

43.10

Antidepressant treatment

 No (n = 59)

41.05 (31.17)

33.47

0.542

 Yes (n = 8)

50.00 (39.84)

37.88

Antipsychotic treatment

 No (n = 63)

40.56 (30.80)

33.21

0.178

 Yes (n = 4)

66.67 (47.14)

46.50

Neurogenic pain treatment

 No (n = 64)

40.45 (31.14)

33.16

0.095

 Yes (n = 3)

77.78 (38.49)

52.00

Notable treatmenta

 No (n = 60)

40.86 (32.52)

32.26

0.122

 Yes (n = 7)

58.73 (21.96)

43.93

Metastasis

 No (n = 60)

38.70 (31.39)

31.93

0.010

 Yesb (n = 7)

71.43 (23.00)

51.71

Metastasis type

  

0.021

 No (n = 60)

38.70 (31.39)

31.93

Ref

 Bone (n = 5)

80.00 (18.26)

56.30

0.011

 Pulmonary (n = 2)

50.00 (23.57)

40.25

0.945

Chemotherapy type

  

0.005

 Palliative (n = 7)

71.43 (23.00)

50.71

Ref

 Adjuvant (n = 44)

34.63 (31.16)

28.47

0.010

 Neoadjuvant (n = 16)

52.08 (28.60)

39.50

0.332

Cyclophosphamide treatmentc

 No (n = 36)

49.38 (31.02)

38.13

0.057

 Yes (n = 31)

33.69 (31.75)

29.21

Capecitabine treatmentc

 No (n = 62)

39.07 (31.09)

32.20

0.007

 Yes (n = 5)

80.00 (18.26)

56.30

  1. Numbers in bold are significant results (p < 0.05)
  2. aThese treatments include benzodiazepines (alprazolam, bromazepam, clonazepam, lorazepam), opioids (tramadol and codeine) and zolpidem
  3. bPatients with metastasis were not considered as having a relapsed breast cancer (thus not excluded) because they had a primary diagnosis of metastatic breast cancer
  4. cOther treatment types did not give significant results
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us